Executive Summary

Real-world evidence (RWE) is becoming a central component of regulatory decision-making in life sciences, expanding beyond a supportive role to directly influence approvals, label expansions, and post-market surveillance. In 2026, regulators are increasingly integrating RWE with clinical trial data to assess safety, effectiveness, and long-term outcomes, particularly for complex therapies and rare diseases.

The U.S. Food and Drug Administration is advancing frameworks that formalize the use of real-world data (RWD) in regulatory submissions. This includes greater acceptance of electronic health records, claims data, and patient registries as part of evidence packages. AI and advanced analytics are enabling more reliable extraction and interpretation of RWE, making it more actionable for regulatory use.

Companies such as Flatiron Health, IQVIA, and Optum are building large-scale data ecosystems that support RWE generation and regulatory integration.

For pharma and biotech leaders, RWE is no longer optional. It is a strategic asset that influences development timelines, regulatory outcomes, and commercial success. Organizations that effectively integrate RWE into their evidence strategies will gain a significant advantage in 2026 and beyond.

Why This Is Accelerating Now

Why Is Real-World Evidence Becoming More Important in 2026?

The growing importance of real-world evidence is driven by limitations in traditional clinical trials and advances in data capabilities.

Clinical trials alone are often insufficient to capture long-term safety, diverse patient populations, and real-world treatment patterns. Regulators are increasingly looking to RWE to fill these gaps.

The availability of healthcare data has expanded significantly. Electronic health records, wearable devices, and digital health platforms are generating continuous streams of patient data that can be analyzed for regulatory insights.

The U.S. Food and Drug Administration has developed clearer guidance on how RWE can be used in regulatory submissions. This includes its use in post-market studies, label expansions, and, in some cases, initial approvals.

AI is also playing a key role by enabling scalable analysis of large and complex datasets, making RWE more reliable and actionable.

Top 5 Real-World Evidence (RWE) Trends in 2026

1. RWE Becomes Decision-Grade Evidence

The most important shift in 2026 is the elevation of real-world evidence from supportive data to decision-grade evidence in regulatory submissions. Regulators, including the U.S. Food and Drug Administration, are increasingly accepting RWE to support safety, effectiveness, and even initial approvals in specific cases.

This trend is especially critical in:

Rare diseases with limited trial populations
Oncology and precision medicine
Long-term safety monitoring

2. Integration of RWE Across the Drug Development Lifecycle

RWE is no longer confined to post-market analysis. In 2026, it is embedded across the full product lifecycle—from early discovery to post-commercialization.

Key integration points include:

Trial design using real-world endpoints
External control arms derived from RWD
Post-market effectiveness and safety tracking

This lifecycle integration improves regulatory alignment and accelerates time to market.

3. AI-Driven RWE Analytics at Scale

Artificial intelligence is transforming how real-world data is processed and analyzed. AI enables scalable, real-time extraction of insights from complex datasets such as electronic health records and unstructured clinical notes.

Leading applications include:

Automated cohort identification
Real-time pharmacovigilance and signal detection
Predictive modeling for treatment outcomes

Organizations leveraging AI for RWE—such as Tempus and Verily—are setting new standards for speed and analytical depth.

4. Expansion of Real-World Data Sources and Ecosystems

The volume and diversity of real-world data are expanding significantly. In 2026, RWE strategies increasingly rely on multi-source data ecosystems that combine:

Electronic health records (EHRs)
Claims and billing data
Wearables and remote monitoring devices
Patient-reported outcomes
Genomic and biomarker data

Companies like Flatiron Health, IQVIA, and Optum are leading this expansion by building integrated data platforms that support regulatory-grade evidence generation.

5. Increased Regulatory Scrutiny on Data Quality and Transparency

As RWE adoption grows, regulators are placing greater emphasis on data quality, traceability, and methodological rigor. Inconsistent or biased datasets can undermine regulatory decisions, making governance a top priority.

Key regulatory expectations include:

Transparent data provenance
Reproducible methodologies
Standardized data formats
Validation of AI models used in analysis

Organizations that invest in strong data governance frameworks will be better positioned for regulatory success.

Key Trends and Insights in 2026

What Are the Biggest Shifts in Real-World Evidence Usage?

The most significant shift is the transition from supplementary to decision-grade evidence.

RWE is no longer used only to support clinical findings. It is increasingly being used to:

Inform regulatory decisions on safety and effectiveness
Support label expansions and new indications
Validate surrogate endpoints used in clinical trials
Monitor post-market outcomes in real time

This shift is particularly important for therapies targeting rare diseases and small patient populations, where traditional trials may be limited.

At the same time, regulators are emphasizing data quality, requiring robust methodologies and transparent data sources.

How Are Companies Integrating Real-World Evidence into Strategy?

Pharma and biotech companies are embedding RWE into their development and regulatory strategies from the outset.

Organizations like Flatiron Health are enabling oncology-focused RWE generation through curated datasets and analytics platforms.

Similarly, IQVIA provides integrated data solutions that combine clinical and real-world datasets for regulatory use.

Common approaches include:

Designing clinical trials that incorporate real-world endpoints
Building partnerships with data providers and healthcare systems
Developing internal capabilities for RWE analysis
Aligning RWE strategies with regulatory requirements early

These strategies help ensure that RWE is credible, relevant, and aligned with regulatory expectations.

What Role Is AI Playing in Real-World Evidence?

AI is critical to unlocking the value of real-world evidence.

AI-driven tools can process large volumes of unstructured data, identify patterns, and generate insights that would be difficult to achieve manually. Companies such as Tempus and Verily are leveraging AI to enhance RWE capabilities.

Key AI applications include:

Extracting structured insights from electronic health records
Identifying patient cohorts for analysis
Detecting safety signals in real time
Supporting predictive modeling of treatment outcomes

However, regulatory agencies require that AI methodologies be transparent and validated, ensuring that insights derived from RWE are reliable.

Where Is Innovation and Investment Moving?

Investment is increasingly focused on building infrastructure for real-world evidence generation and integration.

Pharma companies are prioritizing:

Large-scale data platforms that aggregate diverse data sources
Advanced analytics capabilities for RWE interpretation
Partnerships with healthcare providers and technology companies
Digital tools for continuous data collection

Companies such as Optum are expanding their data ecosystems to support RWE-driven decision-making.

This reflects a broader trend: data is becoming a core asset in regulatory strategy, with RWE playing a central role in innovation and commercialization.

Strategic Implications for Executives

The growing role of real-world evidence requires a shift in how organizations approach regulatory strategy.

Leaders should prioritize integration of RWE into early development. Waiting until post-approval to generate real-world data limits its impact on regulatory outcomes.

Companies must invest in data quality and governance. Regulators expect RWE to meet high standards of accuracy, completeness, and transparency.

Organizations should develop AI capabilities aligned with regulatory expectations. AI can enhance RWE, but only if it is validated and well-documented.

Emerging risks include variability in data quality, evolving regulatory standards, and challenges in integrating RWE with clinical trial data.

Competitive advantage will depend on the ability to combine clinical evidence, real-world data, and advanced analytics into a cohesive regulatory strategy.

Outlook: Real-World Evidence (2026–2028)

Between 2026 and 2028, real-world evidence is expected to become a standard component of regulatory submissions.

The U.S. Food and Drug Administration will likely expand its guidance on RWE, particularly in areas such as initial approvals and digital health.

AI will continue to enhance the analysis and application of RWE, enabling more sophisticated and timely insights.

Global regulatory alignment around RWE may improve, but differences in data privacy and healthcare systems will remain a challenge.

Investment will continue to focus on data infrastructure and analytics capabilities, supporting the integration of RWE into all stages of drug development.

Overall, RWE will play an increasingly important role in shaping regulatory decisions, driving more data-driven and patient-centric approaches to innovation.

Executive FAQ

What is real-world evidence in regulatory decision-making?

Real-world evidence refers to data collected outside clinical trials, such as electronic health records and claims data, used to support regulatory decisions.

How is RWE used by regulators in 2026?

Regulators use RWE for post-market surveillance, label expansions, and increasingly for supporting initial approvals.

What role does AI play in real-world evidence?

AI enables large-scale data analysis, helping extract insights, identify patterns, and support regulatory submissions.

Why is RWE becoming more important now?

Advances in data availability and regulatory frameworks are enabling broader use of real-world evidence.

What is the future of RWE in regulation?

The U.S. Food and Drug Administration is expected to expand its use, making RWE a standard part of regulatory decision-making.

The importance of Real-World evidence is rapidly expanding in modern healthcare regulation. Regulators such as the FDA and EMA increasingly rely on Real-World data to complement traditional clinical trials, helping accelerate decision-making while maintaining safety and effectiveness standards.

What is Real-World Evidence?

Real-World evidence refers to clinical insights derived from data collected outside controlled trials, such as electronic health records, insurance claims, and patient registries.
This Real-World approach enables regulators to understand how treatments perform in everyday clinical settings rather than idealized environments.

Why Real-World Evidence Matters

The rise of Real-World evidence is driven by the need for faster, more efficient drug development. Regulatory agencies use Real-World insights to:

Support drug approvals and label expansions
Monitor post-market safety and effectiveness
Evaluate rare disease treatments where trials are limited

The FDA has already used Real-World evidence in approvals, safety updates, and regulatory decisions across multiple products.

Regulatory Adoption of Real-World Approaches

Global regulators are building frameworks to integrate Real-World evidence into decision-making. The FDA’s structured programs and the EMA’s initiatives like DARWIN EU demonstrate how Real-World data is becoming central to regulatory science.

This shift allows Real-World evidence to serve not just as supportive data, but in some cases as primary evidence in regulatory submissions.

Editorial Team

+ posts

The Growing Role of Real-World Evidence in Regulatory Decision-Making